Legitimate academic controversy and criticism should be allowed from the perspective of medical development, and the law should not be restricted or interfered with.
According to the "Economic Reference Network", the Shanghai Pudong New Area People's Court recently made a first-instance judgment on the case of Geng Meiyu, director of the Academic Director of the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, v. Professor Rao Yi, president of Capital Medical University, and rejected the plaintiff Geng Meiyu's litigation claims.
Geng Meiyu's litigation claims include: Defendant Rao Yi issued an apology statement in a prominent position in his personal WeChat circle of friends, China Science Daily, Science and Technology Daily and Wen Wei Po, which was published once a day for 15 days, apologizing to the plaintiff, eliminating the impact, and restoring his reputation.
Professor Rao Yi
Origins: Rao Yi rebuked Geng Meiyu for falsifying her research on the drug GV-971
On September 6, 2019, the English academic journal Cell Research published an article signed by Geng Meiyu and 26 others entitled "Ganlutna (GV-971) Remodels the Intestinal Flora and Inhibits Intestinal Bacterial Amino Acid Neuroinflammation, Thereby Inhibiting the Progression of Alzheimer's Disease" (Chinese translation).
In this article, Geng proposes that GV-971 has been shown in Phase 3 clinical trials in China to be a sustainable, robust drug that improves cognitive function in patients, inhibits intestinal dysbacteriosis and associated accumulation of phenylalanine/isoleucine, controls neuroinflammation and improves cognitive impairment.
On November 28, 2019, Rao Yi reported Geng Meiyu's fraud in the relevant WeChat group in response to this research article: "This year, Geng Meiyu, a researcher at the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, as a corresponding author, claimed that the drug GV-971 invented by him can treat Alzheimer's disease in mice by extracting intestinal flora. This article is not possible without falsification. Please do something good to wash away the shame of the Chinese scientific community. ”
In this regard, Geng Meiyu believes that Rao Yi has objectively caused damage to her reputation, and the social evaluation has decreased, which has constituted an infringement of her right to reputation.
Since then, the two have had many encounters.
On July 7, 2020, Professor Rao Yi published an article in Cell Research entitled "One Author Should Correct For Neglecting to Cite Previous Literature" (Chinese Translation), pointing out that all the targets and functions of GV-971 help treat Alzheimer's disease, and that it is extremely rare in the biomedical community for a drug to have so many targets to treat a disease together. Geng Meiyu and other 2019 papers are very strange, and actually do not cite the 12 papers related to GV-971 that they have previously published... It's an academic spectacle.
On July 13, Geng Meiyu and others responded in a text message in Cell Research, saying that their research mainly focused on intestinal flora and related neuroinflammation, which is a new mechanism for the treatment of AD by GV-971, and the relevance of the previous 12 articles to the papers involved in the case is too small to be cited.
In addition, Rao Yi also published an article questioning GV-971 in the public account of "Rao Discussion Science", including "the so-called GV-971 for the treatment of Alzheimer's disease is considered a counterfeit drug by many people" and "Without strict investigation, the possibility of GV-971 becoming the largest counterfeiting case in China in the 21st century cannot be ruled out".
